Popular Trials
Cannabinoid
Medical Cannabis for Chronic Pain
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Androgen Replacement Therapy
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
This trial is testing a testosterone injection called Xyosted in older men with Multiple Sclerosis who have low testosterone. The goal is to see if it can improve their energy, mood, thinking skills, and overall quality of life.
Popular Filters
Trials for MS Patients
Antihistamine
Clemastine Fumarate for Multiple Sclerosis
This trial tests Clemastine Fumarate to see if it can repair myelin in patients with relapsing-remitting multiple sclerosis who have chronic brain lesions. The medication helps immature brain cells develop into myelin-producing cells, potentially fixing the damage caused by MS.
Combination Therapies for Multiple Sclerosis
This trial tests four different drugs, alone or in combination, on adults with progressive multiple sclerosis who are not responding well to current treatments. The goal is to see if these drugs can reduce harmful inflammation and immune activity in the brain and spinal fluid.
Antioxidant
N-Acetyl Cysteine for Multiple Sclerosis
This trial is testing whether NAC, a cell-protecting supplement, can help MS patients by reducing cell damage in the brain. MS patients often experience nerve cell damage, and NAC may help by boosting a protective substance called glutathione. NAC has been explored in previous studies for its potential to improve brain glucose metabolism and blood flow in MS patients.
Phase 3 Trials
Immunomodulator
Dimethyl Fumarate for Multiple Sclerosis
This trial is testing the safety and effectiveness of BG00012 in children with RRMS, compared to another disease-modifying treatment. The long-term safety of BG00012 will also be assessed in children who completed Week 96 in Part 1 of the study.
Sphingosine-1-phosphate receptor modulator
Ozanimod for Multiple Sclerosis
This trial will test the effects of ozanimod on cognitive processing speed in 250 subjects with relapsing multiple sclerosis over the course of 36 months. The primary efficacy endpoint is the proportion of subjects with a clinically meaningful increase in raw score of ≥ 4 points or 10% from baseline (improved). There is no planned protocol extension following the end of the study.
Stem Cell Transplant
Stem Cell Transplant vs Best Available Therapy for Multiple Sclerosis
This trial is testing whether AHSCT is better than BAT for treating people with MS who have not responded to other treatments. 156 people will be randomly assigned to either AHSCT or BAT, and followed for 72 months.
Trials With No Placebo
Combination Therapies for Multiple Sclerosis
This trial tests four different drugs, alone or in combination, on adults with progressive multiple sclerosis who are not responding well to current treatments. The goal is to see if these drugs can reduce harmful inflammation and immune activity in the brain and spinal fluid.
Antioxidant
N-Acetyl Cysteine for Multiple Sclerosis
This trial is testing whether NAC, a cell-protecting supplement, can help MS patients by reducing cell damage in the brain. MS patients often experience nerve cell damage, and NAC may help by boosting a protective substance called glutathione. NAC has been explored in previous studies for its potential to improve brain glucose metabolism and blood flow in MS patients.
Immunomodulator
Dimethyl Fumarate for Multiple Sclerosis
This trial is testing the safety and effectiveness of BG00012 in children with RRMS, compared to another disease-modifying treatment. The long-term safety of BG00012 will also be assessed in children who completed Week 96 in Part 1 of the study.
View More Related Trials
Frequently Asked Questions
Introduction to primary progressive multiple sclerosis
What are the top hospitals conducting primary progressive multiple sclerosis research?
In the realm of primary progressive multiple sclerosis (PPMS) clinical trials, several hospitals have emerged as leaders in research and innovation. Located in Cleveland, Ohio, the renowned Cleveland Clinic stands out with six ongoing PPMS trials and a total of four completed trials dedicated to this unique form of multiple sclerosis. Their first recorded PPMS trial took place in 2013, marking a significant milestone in their commitment to finding effective treatments for this condition. On the west coast, the University of California San Francisco is making substantial contributions with five active PPMS trials and three past studies that delve into this complex disease. In 2016, they embarked on their initial journey into PPMS research.
Meanwhile, at Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis in Owosso—a lesser-known but vital player—researchers are currently engaged in five active clinical trials focused on PPMS. Although they have conducted only two previous studies thus far since debuting their first trial dedicated to primary progressive multiple sclerosis just last year in 2020, they are rapidly establishing themselves as an important institution within the field.
Notably contributing to advances from outside traditional hospital settings is Novartis Investigative Site located in Saint Louis where researchers actively conduct four primary progressive MS investigations while having accomplished similar tasks throughpast thirteen years by conducting experiments around this matter from starting it off back at2008.Also present among these esteemed institutions is Johns Hopkins University situatedin Baltimore performingfour current primary progressive MS tests while making substantial strides with one prior study initiated recently just couple years ago during 2018.
These top hospitals and research facilities represent hope not only for those living with primary progressive multiple sclerosis but also underscore the collective dedication towards unraveling its complexities.They remind us that amidst medical challenges there are professionals relentlessly workingto drive progress forwardbringing new possibilities closerfor individuals affected bythis chronic neurological condition
Which are the best cities for primary progressive multiple sclerosis clinical trials?
When it comes to primary progressive multiple sclerosis clinical trials, several cities emerge as key hubs for research and development. Philadelphia, Pennsylvania leads the way with 23 active trials investigating various treatments such as RPC-1063, Ocrelizumab, and Cohort B. Saint Louis, Missouri closely follows with 19 ongoing studies focusing on interventions like RPC-1063 and Nivolumab. New york, New York also plays a significant role with 18 active trials exploring options such as Ocrelizumab and Cohort B. Phoenix, Arizona and Detroit, Michigan stand out as well with 17 and 16 active trials respectively examining potential breakthroughs in treatment methods including Ocrelizumab and RPC-1063. In these cities across different regions of the United States, individuals living with primary progressive multiple sclerosis have access to cutting-edge clinical trials that drive advancements in care for this challenging condition.
Which are the top treatments for primary progressive multiple sclerosis being explored in clinical trials?
Clinical trials are paving the way for advancements in treating primary progressive multiple sclerosis (PPMS). Leading the charge is ocrelizumab, a treatment under investigation in 14 active trials. Since its introduction in 2011, it has been included in nine all-time clinical trials aimed at tackling PPMS. Another promising contender is fenebrutinib, currently being studied in three ongoing trials after its listing in 2020. Autologous hematopoietic stem cell transplantation rounds out the list with two active studies since its debut as a treatment option for PPMS patients back in 2019. These innovative approaches offer hope and potential breakthroughs for those living with this challenging form of multiple sclerosis.
What are the most recent clinical trials for primary progressive multiple sclerosis?
Exciting advancements are being made in the field of primary progressive multiple sclerosis (PPMS) through recent clinical trials. One innovative approach is transcranial direct current stimulation, which has shown promise in early and intermediate stages of PPMS treatment. Another potential therapy is Clemastine Fumarate, currently undergoing Phase 1 and Phase 2 trials to evaluate its efficacy in managing PPMS symptoms. Additionally, a study investigating BIIB091 combined with DRF Standard Dose aims to uncover new possibilities for treating this challenging condition. Notably, Ocrelizumab SC is also being studied as a potential treatment option for PPMS patients in Phase 3 trials. These groundbreaking clinical trials offer hope to individuals living with primary progressive multiple sclerosis by potentially improving their quality of life and slowing disease progression.
What primary progressive multiple sclerosis clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of primary progressive multiple sclerosis (PPMS), offering hope for patients battling this challenging condition. In June 2022, the University of Utah concluded a trial investigating the use of MRI Brain and Cervical Spine to better understand and manage PPMS. Furthermore, Johns Hopkins University completed a trial in June 2018 that explored the potential benefits of Tauroursodeoxycholic Acid as a treatment option for PPMS. These advancements underscore ongoing efforts to improve our understanding and develop effective interventions for individuals with primary progressive multiple sclerosis.